The AZN share price has stumbled. Is now a good time to buy the stock?

The AstraZeneca share price has fallen to a valuation that makes the stock look cheap compared to its growth potential, says this Fool.

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in.

Read More

The content of this article is provided for information purposes only and is not intended to be, nor does it constitute, any form of personal advice. Investments in a currency other than sterling are exposed to currency exchange risk. Currency exchange rates are constantly changing, which may affect the value of the investment in sterling terms. You could lose money in sterling even if the stock price rises in the currency of origin. Stocks listed on overseas exchanges may be subject to additional dealing and exchange rate charges, and may have other tax implications, and may not provide the same, or any, regulatory protection as in the UK.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

The AstraZeneca (LSE: AZN) share price outperformed the FTSE 100 by a substantial margin in 2020. However, over the past 12 months, the stock has lagged the UK’s leading equity index.

Excluding dividends, shares in AstraZeneca have returned -1%. Meanwhile, the lead index has added nearly 18%. Over the past month, shares in the pharmaceutical giant have lost 4%, compared to a flat FTSE 100. 

This performance seems to suggest the market has become disinterested in the enterprise. But I think that could be a mistake. Indeed, the company’s latest trading update indicates to me the group is stronger than ever. 

AZN share price growth 

AstraZeneca has risen to fame over the last year as the company’s cheap and effective coronavirus vaccine has saved tens of thousands of lives. The decision to sell the vaccine at cost to many customers has generated a spate of good publicity for the group. In the second quarter, the company generated $900m of sales from its coronavirus vaccine. In the same period, US drug giant Pfizer reported sales of $7.8bn for its treatment.

The company’s vaccine catapulted it onto the front pages of newspapers worldwide, but it’s only a tiny part of the overall business. In the second quarter, group sales totalled $8.2bn. Rising sales of treatments to emerging markets and oncology helped boost revenues 31% year-on-year. 

Based on these revenue trends, City analysts expect the company to report earnings per share of around 523p this year. This suggests the AZN share price is trading at a forward price-to-earnings (P/E) multiple of 22. Further growth of 28% is expected in 2022. Based on these targets, the stock’s selling at a 2022 P/E of 17.3. 

These numbers don’t look to me to be particularly demanding. The stock’s trading at roughly the same valuation as its FTSE 100 peer, Hikma. What’s more, a 2022 P/E of 17.3 implies the AZN share price is dealing at a PEG ratio of less than one. This implies the stock may offer growth at a reasonable price. 

Of course, these are just forecasts. There’s no guarantee the company will hit earnings projections in the years ahead. 

Risks and challenges

If the company’s growth doesn’t live up to expectations, the stock may be expensive at current levels. Challenges the group may face include higher research and development costs. Regulatory delays in approving new treatments may also hold back growth.

AstraZeneca’s sales have also faced pressure in the past as its treatments have lost patent protection, allowing competitors to manufacture the same drug at a lower cost. 

Despite these potential headwinds, I think the recent performance of the AZN share price could offer an opportunity. That’s why I’d buy the stock for my portfolio today.

The national champion has a market-leading position in vaccines and oncology, and its current valuation suggests the market is overlooking its long-term growth potential. 

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

Rupert Hargreaves has no position in any of the shares mentioned. The Motley Fool UK has recommended Hikma Pharmaceuticals. Views expressed on the companies mentioned in this article are those of the writer and therefore may differ from the official recommendations we make in our subscription services such as Share Advisor, Hidden Winners and Pro. Here at The Motley Fool we believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Investing Articles

Up 26%, can the BT share price really push higher still?

The BT share price has surged on several catalysts in 2024, but there’s evidence to suggest that the stock could…

Read more »

Man writing 'now' having crossed out 'later', 'tomorrow' and 'next week'
Investing Articles

What are the best dividend shares to buy right now?

As shares in B&M European Value Retail have fallen, the dividend yield has reached a 10-year high. Should investors be…

Read more »

Surprised Black girl holding teddy bear toy on Christmas
Investing Articles

My favourite FTSE 100 passive income stock that keeps the Christmas coffers full

The holiday season is expensive and can leave many consumers struggling to make ends meet. Here’s how I use a…

Read more »

Investing Articles

The latest growth forecasts suggest the Glencore share price will hit 555p!

Harvey Jones has been disappointed by the performance of the Glencore share price since he bought the commodity stock last…

Read more »

Dividend Shares

A closer look at the 11% dividend yield forecast for Phoenix Group shares

Phoenix Group shares have one of the highest dividend yields in the FTSE 100 index today. Could this be a…

Read more »

Investing Articles

If I’d put £25,000 into the FTSE 350 at the start of 2024, here’s how much I’d have today!

Many FTSE shares have rebounded this year as interest rates look set to keep heading lower and market appetite for…

Read more »

Investing Articles

Up 40%, but experts forecast the easyJet share price could soon hit 664p! Time to buy?

The easyJet share price has been flying lately and stock analysts are predicting more fun to come. But there's only…

Read more »

Storytelling image of a multiethnic senior couple in love - Elderly married couple dating outdoors, love emotions and feelings
Investing Articles

Worried about tax raids? Here’s how I’m targeting a £44,526 passive income with shares

Investing in a Self-Invested Personal Pension (SIPP) or Individual Savings Account (ISA) can supercharge one's passive income, says Royston Wild.

Read more »